Search
EHA Statement on COVID-19
The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).
Read moreNovel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read moreNew GFI1B variants in bleeding and platelet disorders
Platelets restrict blood loss upon vessel damage by formation of a clot (thrombus). Recently, we reported a family with a bleeding and platelet disorder (BPD), which was caused by a defect in the gene GFI1B1.
Read moreSanquin Blood Supply will culture erythrocytes for transfusion purposes
ABO-Rh-D matched transfusions result in alloimmunisation in 3-5% of recipients. Once allo-immunized, it may become very difficult to find appropriate donor erythrocytes, especially when multiple antibodies or rare combinations of antibodies are present.
Read moreCurriculum-Exam Committee
Current committee members
Jose Tomás Navarro Ferrando, Spain (Chair)
Marielle Wondergem, The Netherlands (Vice-Chair and Progress test lead)
Alicia Rovó, Switzerland (Representative, Swiss Society)
Regular members
Gunnar Birgegård, Sweden
Roza Chaireti, Sweden
Carlos Fernández de Larrea, Spain
Mahesh Prahladan, United Kingdom
Ulla Wartiovaara-Kautto, Finland
AimTo promote harmonization in hematology training…
Code of Conduct
The guidelines below govern the publication of, and commentary on the EHA Hematology Hub. Please read through them before participating. 1. Abide by the rules that normally apply.
Read more